Pfizer to Buy Rights of Stem Cell Therapy from Athersys (NASDAQ:ATHX)
December 21st, 2009
No comments
Athersys (ATHX) is a bio-pharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. ATHX is developing MultiStem, a patented adult-derived “off-the-shelf” stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. (www.athersys.com)
Categories: Independent Equity Research, Stem Cell Technology
Opexa Therapeutics develops of patient-specific cellular therapies for the treatment of autoimmune diseases. OPXA is developing Tovaxin®, an individualized cellular immunotherapy treatment in Phase IIb clinical development for multiple sclerosis (MS). Tovaxin® is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections triggering a potent immune response against specific subsets of autoreactive T-cells known to attack myelin, believed to be a primary cause of MS attacks and nervous system damage. 
Neuralstem is a biotechnology company focused on developing and commercializing human neural stem cell technology in the field of regenerative medicine 
NeoStem is engaged in the business of developing stem cell therapies, pursuing anti-aging initiatives and is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. (
Interim RESTORE 2 results presented (12/12/09) demonstrate that 
